NextCure, Inc.
NXTC Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.98
KIRA · Stoqly’s AI analyst, in plain words
- NextCure, Inc. lost $55.8M in fiscal 2025.
Market cap
$26.4M
P/E
—
Revenue
—
Net income
−$55.8M
Free cash flow
—
Operating margin
—
NextCure, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$55.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What NextCure, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- NextCure, Inc.
- CIK
- 0001661059
NextCure, Inc. · NXTC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$69.4M | −$74.7M | −$62.7M | −$55.7M | −$55.8M |
| Diluted EPS | −$2.51 | −$2.69 | −$2.25 | −$23.88 | −$19.65 |
| Cash | |||||
| Cash from operations | −$57.3M | −$53.9M | −$53.0M | −$40.8M | −$49.6M |
| Capital expenditure | $2.4M | $2.1M | $0.8M | $0.5M | — |
| Free cash flow | −$59.6M | −$56.0M | −$53.8M | −$41.3M | — |
| Share count change | 0.3% | 0.5% | 0.3% | −91.6% | 22.0% |
| Debt and strength | |||||
| Cash and short-term investments | $12.3M | $26.6M | $13.1M | $27.7M | $26.0M |
| Debt incl. finance leases | $0.0M | $0.0M | — | — | — |
| Shareholders' equity | $233M | $168M | $114M | $65.5M | $34.9M |
| Current ratio | 34.5x | 18.0x | 16.4x | 7.5x | 4.1x |
| Returns and quality | |||||
| Return on capital | −25.3% | −42.6% | — | — | — |
| Return on equity | −26.3% | −37.3% | −44.5% | −61.9% | −111.2% |
| Return on tangible equity | −29.7% | −44.6% | −54.8% | −85.0% | −159.8% |
| Piotroski F-score | 3 | 1 | — | — | — |
| Altman Z'' | 28.7 | 8.7 | 2.4 | −10.8 | −29.3 |
Insiders bought, 12 months
$1.6M
1 insider
Insiders sold, 12 months
$0.2M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NextCure, Inc. · NXTC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.98 a share, the company is worth $26.4M.
Source: SEC EDGAR XBRL filings (CIK 0001661059). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.